


Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA
